JP2014055156A5 - - Google Patents

Download PDF

Info

Publication number
JP2014055156A5
JP2014055156A5 JP2013230960A JP2013230960A JP2014055156A5 JP 2014055156 A5 JP2014055156 A5 JP 2014055156A5 JP 2013230960 A JP2013230960 A JP 2013230960A JP 2013230960 A JP2013230960 A JP 2013230960A JP 2014055156 A5 JP2014055156 A5 JP 2014055156A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
leukemia
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013230960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014055156A (ja
Filing date
Publication date
Priority claimed from US11/600,332 external-priority patent/US7842815B2/en
Application filed filed Critical
Publication of JP2014055156A publication Critical patent/JP2014055156A/ja
Publication of JP2014055156A5 publication Critical patent/JP2014055156A5/ja
Pending legal-status Critical Current

Links

JP2013230960A 2006-11-15 2013-11-07 Bclタンパクの結合パートナーとの相互作用を阻害するための化合物および方法 Pending JP2014055156A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/600,332 US7842815B2 (en) 2004-06-17 2006-11-15 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US11/600,332 2006-11-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009537198A Division JP2010510214A (ja) 2006-11-15 2007-11-14 Bclタンパクの結合パートナーとの相互作用を阻害するための化合物および方法

Publications (2)

Publication Number Publication Date
JP2014055156A JP2014055156A (ja) 2014-03-27
JP2014055156A5 true JP2014055156A5 (cg-RX-API-DMAC10.html) 2014-07-03

Family

ID=39064388

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009537198A Pending JP2010510214A (ja) 2006-11-15 2007-11-14 Bclタンパクの結合パートナーとの相互作用を阻害するための化合物および方法
JP2013230960A Pending JP2014055156A (ja) 2006-11-15 2013-11-07 Bclタンパクの結合パートナーとの相互作用を阻害するための化合物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009537198A Pending JP2010510214A (ja) 2006-11-15 2007-11-14 Bclタンパクの結合パートナーとの相互作用を阻害するための化合物および方法

Country Status (20)

Country Link
US (2) US7842815B2 (cg-RX-API-DMAC10.html)
EP (1) EP2094673B1 (cg-RX-API-DMAC10.html)
JP (2) JP2010510214A (cg-RX-API-DMAC10.html)
KR (1) KR101530721B1 (cg-RX-API-DMAC10.html)
CN (1) CN101583606B (cg-RX-API-DMAC10.html)
AU (1) AU2007319848B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0718606A2 (cg-RX-API-DMAC10.html)
CA (1) CA2669596C (cg-RX-API-DMAC10.html)
EC (1) ECSP099398A (cg-RX-API-DMAC10.html)
ES (1) ES2537762T3 (cg-RX-API-DMAC10.html)
GT (1) GT200900123A (cg-RX-API-DMAC10.html)
IL (1) IL198597A (cg-RX-API-DMAC10.html)
MA (1) MA31067B1 (cg-RX-API-DMAC10.html)
MX (1) MX2009005184A (cg-RX-API-DMAC10.html)
MY (1) MY156754A (cg-RX-API-DMAC10.html)
NO (1) NO20092306L (cg-RX-API-DMAC10.html)
NZ (1) NZ577243A (cg-RX-API-DMAC10.html)
RU (1) RU2449996C2 (cg-RX-API-DMAC10.html)
TN (1) TN2009000182A1 (cg-RX-API-DMAC10.html)
WO (1) WO2008060569A1 (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
BRPI0907754A2 (pt) * 2008-02-08 2015-07-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos terapêuticos
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
CA2863774C (en) 2012-02-06 2016-08-16 Discoverx Corporation Detection of intracellular binding events by measuring protein abundance
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
CN103656642A (zh) * 2012-08-31 2014-03-26 中国科学院上海生命科学研究院 预防和治疗结直肠癌的方法和试剂
ES2774932T3 (es) 2012-11-14 2020-07-23 Cj Cheiljedang Corp Producción de sales de 4-hidroxibutirato utilizando materias primas de base biológica
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
IL295472B2 (en) 2016-03-28 2024-10-01 Presage Biosciences Inc Pharmaceutical combinations for the treatment of cancer
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
SI3606928T1 (sl) * 2017-04-05 2023-02-28 President And Fellows Of Harvard College Makrociklična spojina in njene uporabe
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
EP4175644A1 (en) 2020-07-06 2023-05-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
AU649421B2 (en) 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
US5294617A (en) * 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
ATE181735T1 (de) * 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
CA2174838A1 (en) 1993-11-24 1995-06-01 John Wityak Novel isoxazoline and isoxazole fibrinogen receptor antagonists
AU684887B2 (en) 1994-03-09 1998-01-08 Pfizer Inc. Isoxazoline compounds as inhibitors of TNF release
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (de) 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
WO1998006694A1 (en) 1996-08-16 1998-02-19 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
EP0986384B1 (en) 1997-05-07 2012-02-22 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
WO2001016115A1 (en) 1999-09-01 2001-03-08 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolidines
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
ATE474568T1 (de) 2001-05-30 2010-08-15 Univ Michigan Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
KR101195351B1 (ko) 2004-06-17 2012-10-29 인피니티 디스커버리, 인코포레이티드 Bcl 단백질과 결합 파트너와의 상호작용을 억제하는화합물 및 방법
WO2006009907A2 (en) * 2004-06-17 2006-01-26 Infinity Pharmaceuticals, Inc. Isoxazolidine compounds for treatment of bacterial infections
TWI403320B (zh) * 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法

Similar Documents

Publication Publication Date Title
JP2010510214A5 (cg-RX-API-DMAC10.html)
Huttunen et al. Prodrugs—from serendipity to rational design
Naksuriya et al. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment
RU2468016C2 (ru) СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl СО СВЯЗЫВАЮЩИМИ ПАРТНЕРАМИ
WO2008027445A3 (en) Combination with bis(thiohydrazide amides) for treating cancer
WO2015006740A3 (en) Oligonucleotide-ligand conjugates and process for their preparation
JP2017517520A5 (cg-RX-API-DMAC10.html)
SI3210965T1 (sl) Postopek za pripravo (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenola
WO2010135396A3 (en) Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
BRPI0814542A2 (pt) Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
EP4299134A3 (en) Fap-activated therapeutic agents, and uses related thereto
HRP20231163T1 (hr) Prolijekovi glutaminskih analoga
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
JP2010001302A5 (cg-RX-API-DMAC10.html)
CO7310528A2 (es) Composición farmacéutica recubierta que contiene regorafenib
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
HK1254645A1 (zh) 冻乾药物组合物
IN2014MU00303A (cg-RX-API-DMAC10.html)
PH12014501495B1 (en) Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
CR20160037A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
JP2017511340A5 (cg-RX-API-DMAC10.html)
EA201301265A1 (ru) Способ лечения солидных злокачественных опухолей, включая прогрессирующие или метастатические солидные злокачественные опухоли
CL2011002774A1 (es) Combinacion farmaceutica que comprende cabazitaxel y capecitabina, en forma de base, sal, hidrato o solvato; uso para el tratamiento del cancer de mama metastasico.
CN110049765A (zh) 一种组合、其应用及治疗方法
WO2012131487A3 (en) Compositions and methods for the treatment of cancer